Leronlimab Safety and Brain Inflammation in Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older with diagnosed mild-to-moderate memory loss or Alzheimer's disease (confirmed by a cognitive test)
- Able to complete memory and thinking tests, including a specific screening test (MoCA score above 11)
- Normal or non-concerning heart rhythm on an ECG test
- If taking Alzheimer's or brain-related medications, must be on the same dose for at least 12 weeks before starting the trial
- Have a study partner (family member or friend) who can help support you and provide information about your condition
- Able to undergo MRI and PET brain scans without contraindications (no pacemakers, metal implants, or severe claustrophobia)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world safety information from people taking the Alzheimer's drug LEQEMBI (also known as lecanemab). It helps doctors understand how well the medicine works outside of clinical trials and what side effects may occur.
This study tests whether adding a new drug called lencanizumab to standard Alzheimer's medications can help slow memory loss in people with early Alzheimer's. It's an observational study, meaning you'll receive the treatment as part of your regular care, and researchers will track your progress.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests whether the drug lecanemab works better at different doses for people with early Alzheimer's disease or mild cognitive impairment caused by Alzheimer's. It aims to see if the drug can slow memory loss in real-world situations.
Hear when a new Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.